CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 6 enrolled
Drug / intervention
Placebo oral capsule +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03640052
NCT03640052Phase 2Completed
CompareCT.gov

Pharmacological Activation of Hypoglossal Motor Nucleus for Obstructive Sleep Apnea

Brigham and Women's Hospital·interventional·Posted Aug 21, 2018·Updated Feb 24, 2020

In Brief

A Phase 2 clinical trial evaluating Placebo oral capsule, LTM1201L, and 3 other interventions for Obstructive Sleep Apnea. Completed, enrolled 6 participants across 2 sites.

Detailed Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of LTM1201L, LTM1201LN, LTM1201LB, LTM1201LD administered before sleep on OSA phenotype traits and OSA severity during sleep.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedAug 21, 2018
Enrollment StartOct 30, 2018
Primary CompletionSep 30, 2019
Study CompletionDec 31, 2019
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 7.9 years ago

Interventions

Placebo oral capsuledrug

Placebo capsule before sleep

LTM1201Ldrug

LTM1201L capsule before sleep

LTM1201LNdrug

LTM1201LN capsule before sleep

LTM1201LBdrug

LTM1201LB capsule before sleep

LTM1201LDdrug

LTM1201LD capsule before sleep